|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
<i>Gold standard</i> therapy with statins and the more recently developed <i>proprotein convertase subtilisin/kexin type 9</i> (PCSK9) inhibitors have improved health conditions among CVD patients by lowering <i>low density lipoprotein</i> (LDL) cholesterol.
|
31191301 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
PCSK9 inhibition represents a very promising target for reducing LDL-C levels and decreasing the risk of atherosclerotic cardiovascular diseases, but human clinical trials will be crucial to assess the potency and safety of PCSK9 inhibitors.
|
21619378 |
2011 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel target for controlling plasma levels of low-density lipoprotein cholesterol (LDL-C) and decreasing the risk of cardiovascular diseases.
|
22311433 |
2012 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
|
25278291 |
2014 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
PCSK9 GOF mutation carriers have elevated LDL-C levels and are at high risk of premature cardiovascular disease.
|
26374825 |
2015 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of low-density lipoprotein cholesterol and cardiovascular disease risk, and is an emerging therapeutic target.
|
28093849 |
2017 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
PCSK9 inhibitors are found in the model only to be cost-effective in secondary prevention for older patients with high absolute risk of CVD.
|
28444187 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease.
|
30112987 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a single-turnover protease which regulates serum low-density lipoprotein (LDL) levels and, consequently, cardiovascular disease.
|
30222160 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
AlteredExpression
|
group |
BEFREE |
PCSK9 is a secreted protein that regulates plasma cholesterol levels and cardiovascular disease risk.
|
30251625 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes LDL receptor (LDLR) degradation, increasing plasma levels of LDL cholesterol and the risk of cardiovascular disease.
|
30617148 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
AlteredExpression
|
group |
BEFREE |
PCSK-9 levels were higher in statin users and patients with a history of cardiovascular disease.
|
30921469 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
AlteredExpression
|
group |
BEFREE |
PCSK9 inhibitors potently lower plasma LDL-C levels in T2DM patients and reduce risk for the development of cardiovascular disease.
|
31002456 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Proprotein convertase subtilisin/kexin type-9 (PCSK9), a molecular determinant of low-density lipoprotein (LDL) receptor (LDLR) fate, has emerged as a promising therapeutic target for atherosclerotic cardiovascular diseases.
|
31419281 |
2020 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
PCSK9 regulates LDL receptor degradation and plays key roles in hypercholesterolemia and related cardiovascular diseases.
|
31593224 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
A Cochrane review with meta-analysis showed controversial results about the efficacy of PCSK9 antibodies in the prevention of cardiovascular diseases.
|
29334796 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
A decade after our discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in cholesterol metabolism through the identification of the first mutations leading to hypercholesterolemia, PCSK9 has become one of the most promising targets in cholesterol and cardiovascular diseases.
|
25052769 |
2014 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
A published Markov model was adopted to investigate lifetime outcomes: (1) number of recurrent CVD events prevented, (2) quality-adjusted life-years (QALYs) gained, (3) costs and (4) incremental cost-effectiveness ratios (ICERs) of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) and ezetimibe added to statin therapy.
|
31243736 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases.
|
31400268 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
A risk factor for cardiovascular disease (CVD), mutant PCSK9, was expressed in APP/PS1 mice to study the CVD-Alzheimer's disease inter-relationship.
|
30124449 |
2018 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Although PCSK9 inhibitors were shown to reduce the risk of cardiovascular disease, a warning was issued concerning their possible impact on cognitive functions.
|
31437157 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Although lipid-lowering drugs, especially statins, and recently also PCSK9 inhibitors can reduce LDL cholesterol (LDL-C) and decrease the risk for cardiovascular disease (CVD) including coronary artery disease (CAD) events most efficiently, only 5-10% of high-risk cardiovascular patients reach the target values recommended by international guidelines.
|
31818446 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Although short-term trials have suggested that PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors are safe and reduce risk of cardiovascular diseases, their long-term safety is unclear.
|
30645167 |
2019 |
|
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
As of now, in adjunct to diet, alirocumab and evolocumab are the only approved PCSK9 mAbs for the treatment of adult patients with severe clinical atherosclerotic CVD already at maximally-tolerated statin therapy and require additional LDL-C lowering.
|
28060539 |
2017 |
|
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
|
29593095 |
2018 |